{ "run": { "id": "cmnqyvh9300isp658h4zcjfh3", "region": "BR", "assetId": "cmlr6u213001dqj32i4rs2ioy", "ticker": "HAPV3", "snapshotId": "cmnqyvh8y00iqp658qck6bl8v", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T04:18:20.053Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnqyvh8y00iqp658qck6bl8v", "assetId": "cmlr6u213001dqj32i4rs2ioy", "asOf": "2026-04-08T21:30:33.000Z", "snapshot": { "asOf": "2026-04-08T21:30:33.000Z", "quote": { "asOf": "2026-04-08T21:30:33.000Z", "open": 11.75, "price": 11.19, "dayLow": 11.19, "volume": 15401400, "dayHigh": 12.04, "currency": "BRL", "prevClose": 11.27, "week52Low": 7, "week52High": 44.85 }, "fundamentals": { "pe": 0, "beta": 0, "epsTTM": -0.3009774, "fcfTTM": 1550545000, "growth": { "epsYoy": 0.43660858, "revenueYoy": 3.2606955 }, "sector": "Saúde", "margins": { "net": -0.0045022615, "gross": 0.11791844, "operating": 0.04612898 }, "website": "https://www.hapvidandi.com.br/", "industry": "Serviços Médicos Hospitalares", "pegRatio": -0.10743939, "ebitdaTTM": 2326337000, "forwardPe": 0, "marketCap": 5104453753, "totalCash": 7863422000, "totalDebt": 19336837000, "debtEquity": 0.40076122, "quickRatio": 1.8335247, "revenueTTM": 31577242000, "companyName": "Hapvida Participacoes e Investimentos SA", "priceToBook": 0.013821685, "currentRatio": 1.898895, "dividendYield": null, "returnOnAssets": -0.0019666532, "returnOnEquity": -0.0029464914, "analystOpinions": 0, "businessSummary": "A Hapvida Participações e Investimentos S.A., listada na B3 sob o ticker HAPV3, tem origem em 1979 e atua no setor de saúde suplementar no Brasil. A companhia opera modelo verticalizado de assistência médica e odontológica, com rede própria e credenciada.\n\nSeus negócios incluem comercialização e gestão de planos de saúde e odontológicos, hospitais, clínicas, pronto atendimento e serviços diagnósticos. Após integração com a NotreDame Intermédica, o grupo ampliou escala nacional e base de beneficiários em diferentes perfis de cobertura.\n\nNo ambiente competitivo, a empresa concorre com operadoras de planos e grupos integrados de saúde, com foco em custo assistencial, sinistralidade e eficiência de rede. O setor é influenciado por dinâmica regulatória, inflação médica e capacidade de gestão de utilização dos serviços.\n\nA atuação é nacional, com presença relevante em diversas regiões e rede a…", "enterpriseValue": 12140315000, "analystTargetLow": 0, "analystTargetHigh": 0, "analystTargetMean": 0, "fullTimeEmployees": 60000, "sharesOutstanding": 65000000, "enterpriseToEbitda": 5.21864, "analystTargetMedian": 0, "enterpriseToRevenue": 0.3844641, "operatingCashflowTTM": 2063160100, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T04:18:20.050Z" }, "results": [ { "id": "cmnqyvh9500iup6586e4b9lvr", "runId": "cmnqyvh9300isp658h4zcjfh3", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"HAPV3\",\"currency\":\"BRL\",\"current_price\":11.19,\"target_price_6m\":12.50,\"target_price_12m\":13.40,\"recommendation\":\"BUY\",\"confidence\":0.58,\"thesis_bullets\":[\"Vertically integrated healthcare model offers structural cost advantages in Brazil\",\"EV/EBITDA of ~5.2x is cheap versus healthcare peers if margins recover\",\"Positive FCF of BRL 1.55B supports deleveraging despite negative net income\",\"NDI merger integration still creating operational drag but improving sequentially\",\"High leverage (BRL 19.3B debt) limits upside and creates refinancing risk\"],\"key_drivers\":[{\"driver\":\"Medical loss ratio (sinistralidade) trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Post-merger integration synergies realization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Brazilian interest rate environment on debt servicing\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Organic beneficiary growth and ticket repricing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory changes in supplementary health (ANS)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Operating leverage as revenue scales on fixed network\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Medical inflation above plan price adjustments\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Free cash flow conversion improvement\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Sustained high Selic rates increase debt service burden on BRL 19.3B total debt\",\"Failure to improve operating margin beyond 4.6% could compress equity value further\",\"Regulatory intervention on plan pricing or network adequacy standards\",\"Competitive pressure from SulAmérica/Rede D'Or eroding market share in key regions\",\"Integration missteps leading to beneficiary churn or quality deterioration\",\"Macro slowdown reducing formal employment and group plan enrollment\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.07,\"wacc\":0.145,\"terminal_multiple\":6.5},\"scenarios\":{\"bear\":{\"target_price\":8.00,\"prob\":0.25,\"notes\":\"Margin stagnation, rising debt costs, and beneficiary losses push stock toward 52-week lows.\"},\"base\":{\"target_price\":13.40,\"prob\":0.50,\"notes\":\"Gradual margin improvement to ~6%, steady deleveraging, and moderate beneficiary growth.\"},\"bull\":{\"target_price\":18.00,\"prob\":0.25,\"notes\":\"Full synergy capture lifts EBITDA margin above 10%, accelerating deleveraging and re-rating.\"}},\"method_notes\":\"EV/EBITDA-based valuation anchored on forward EBITDA estimates assuming gradual margin recovery post-NDI integration. Applied 6-6.5x forward EBITDA range (discount to global healthcare peers given leverage). Net debt of ~BRL 11.5B subtracted. FCF yield cross-check supports modest upside. Confidence limited by negative net income, high leverage, and macro sensitivity. 52-wk high of 44.85 reflects pre-correction levels not used as anchor. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained high Selic rates increase debt service burden on BRL 19.3B total debt", "Failure to improve operating margin beyond 4.6% could compress equity value further", "Regulatory intervention on plan pricing or network adequacy standards", "Competitive pressure from SulAmérica/Rede D'Or eroding market share in key regions", "Integration missteps leading to beneficiary churn or quality deterioration", "Macro slowdown reducing formal employment and group plan enrollment" ], "ticker": "HAPV3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual margin improvement to ~6%, steady deleveraging, and moderate beneficiary growth.", "target_price": 13.4 }, "bear": { "prob": 0.25, "notes": "Margin stagnation, rising debt costs, and beneficiary losses push stock toward 52-week lows.", "target_price": 8 }, "bull": { "prob": 0.25, "notes": "Full synergy capture lifts EBITDA margin above 10%, accelerating deleveraging and re-rating.", "target_price": 18 } }, "confidence": 0.58, "assumptions": { "wacc": 0.145, "revenue_cagr_3y": 0.08, "terminal_multiple": 6.5, "ebit_margin_target": 0.07 }, "key_drivers": [ { "driver": "Medical loss ratio (sinistralidade) trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Post-merger integration synergies realization", "impact": "HIGH", "direction": "POS" }, { "driver": "Brazilian interest rate environment on debt servicing", "impact": "HIGH", "direction": "NEG" }, { "driver": "Organic beneficiary growth and ticket repricing", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory changes in supplementary health (ANS)", "impact": "MED", "direction": "NEG" }, { "driver": "Operating leverage as revenue scales on fixed network", "impact": "MED", "direction": "POS" }, { "driver": "Medical inflation above plan price adjustments", "impact": "MED", "direction": "NEG" }, { "driver": "Free cash flow conversion improvement", "impact": "MED", "direction": "POS" } ], "method_notes": "EV/EBITDA-based valuation anchored on forward EBITDA estimates assuming gradual margin recovery post-NDI integration. Applied 6-6.5x forward EBITDA range (discount to global healthcare peers given leverage). Net debt of ~BRL 11.5B subtracted. FCF yield cross-check supports modest upside. Confidence limited by negative net income, high leverage, and macro sensitivity. 52-wk high of 44.85 reflects pre-correction levels not used as anchor. Not investment advice.", "current_price": 11.19, "recommendation": "BUY", "thesis_bullets": [ "Vertically integrated healthcare model offers structural cost advantages in Brazil", "EV/EBITDA of ~5.2x is cheap versus healthcare peers if margins recover", "Positive FCF of BRL 1.55B supports deleveraging despite negative net income", "NDI merger integration still creating operational drag but improving sequentially", "High leverage (BRL 19.3B debt) limits upside and creates refinancing risk" ], "target_price_6m": 12.5, "target_price_12m": 13.4 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 41598, "createdAt": "2026-04-09T04:18:20.053Z", "usage": { "inputTokens": 3763, "outputTokens": 1862, "costUsd": 0.065365 } }, { "id": "cmnqyvh9500ixp658z7kh1vpm", "runId": "cmnqyvh9300isp658h4zcjfh3", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"HAPV3\",\n \"currency\": \"BRL\",\n \"current_price\": 11.19,\n \"target_price_6m\": 11.40,\n \"target_price_12m\": 11.75,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Vertical integration model in Brazilian healthcare sector.\",\n \"Post-merger synergy potential from NotreDame integration.\",\n \"Positive operating cash flow despite negative net margin.\",\n \"Low price-to-book ratio indicating possible undervaluation.\",\n \"High debt and regulatory risks tempering upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth from market expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Cost control and synergy realization\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction efforts\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory changes in healthcare\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic conditions affecting demand\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Integration risks with NotreDame\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"EBITDA margin improvement\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competition in healthcare sector\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Regulatory policy changes\", \"High leverage and interest rate risk\", \"Execution risks in integration\", \"Economic downturn reducing spending\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.05,\n \"wacc\": 0.1,\n \"terminal_multiple\": 6.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 10.0, \"prob\": 0.3, \"notes\": \"Poor integration and regulatory headwinds pressure margins.\" },\n \"base\": { \"target_price\": 11.75, \"prob\": 0.5, \"notes\": \"Steady growth and cost improvements drive modest upside.\" },\n \"bull\": { \"target_price\": 13.5, \"prob\": 0.2, \"notes\": \"Strong synergy realization and market share gains.\" }\n },\n \"method_notes\": \"DCF with growth and margin assumptions; targets reflect balanced risk-reward. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI_Equity_Model", "risks": [ "Regulatory policy changes", "High leverage and interest rate risk", "Execution risks in integration", "Economic downturn reducing spending" ], "ticker": "HAPV3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and cost improvements drive modest upside.", "target_price": 11.75 }, "bear": { "prob": 0.3, "notes": "Poor integration and regulatory headwinds pressure margins.", "target_price": 10 }, "bull": { "prob": 0.2, "notes": "Strong synergy realization and market share gains.", "target_price": 13.5 } }, "confidence": 0.6, "assumptions": { "wacc": 0.1, "revenue_cagr_3y": 0.05, "terminal_multiple": 6, "ebit_margin_target": 0.05 }, "key_drivers": [ { "driver": "Revenue growth from market expansion", "impact": "MED", "direction": "POS" }, { "driver": "Cost control and synergy realization", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction efforts", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory changes in healthcare", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic conditions affecting demand", "impact": "MED", "direction": "NEG" }, { "driver": "Integration risks with NotreDame", "impact": "MED", "direction": "NEG" }, { "driver": "EBITDA margin improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition in healthcare sector", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF with growth and margin assumptions; targets reflect balanced risk-reward. Not investment advice.", "current_price": 11.19, "recommendation": "HOLD", "thesis_bullets": [ "Vertical integration model in Brazilian healthcare sector.", "Post-merger synergy potential from NotreDame integration.", "Positive operating cash flow despite negative net margin.", "Low price-to-book ratio indicating possible undervaluation.", "High debt and regulatory risks tempering upside." ], "target_price_6m": 11.4, "target_price_12m": 11.75 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 364, "createdAt": "2026-04-09T04:18:20.053Z", "usage": { "inputTokens": 2240, "outputTokens": 3924, "costUsd": 0.002275 } }, { "id": "cmnqyvh9500ivp6581y0lqnxj", "runId": "cmnqyvh9300isp658h4zcjfh3", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-HAPV3\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"HAPV3\",\n \"currency\": \"BRL\",\n \"current_price\": 11.19,\n \"target_price_6m\": 12.00,\n \"target_price_12m\": 13.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Verticalized model offers structural cost advantages over traditional fee-for-service healthcare peers.\",\n \"GNDI integration synergies are gradually materializing, supporting long-term margin expansion.\",\n \"High medical loss ratio (MLR) remains a near-term headwind but shows signs of stabilization.\",\n \"Elevated financial leverage pressures net income amid a high interest rate environment.\",\n \"Valuation at ~5.2x EV/EBITDA largely prices in current operational and macroeconomic headwinds.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medical Loss Ratio (MLR)\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Ticket Price Adjustments\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GNDI Integration Synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Selic Interest Rate\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Beneficiary Base Growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital Capacity Utilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Persistent inflation in medical costs, drugs, and hospital supplies.\",\n \"Regulatory changes by ANS limiting price adjustments or mandating new coverages.\",\n \"High interest rates increasing the burden of the 19.3B BRL total debt.\",\n \"Increased competition from regional verticalized players and traditional insurers.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.08,\n \"wacc\": 0.125,\n \"terminal_multiple\": 6.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 8.50,\n \"prob\": 0.25,\n \"notes\": \"MLR remains elevated and high interest rates severely pressure cash flow generation.\"\n },\n \"base\": {\n \"target_price\": 13.00,\n \"prob\": 0.55,\n \"notes\": \"Gradual MLR improvement and steady realization of GNDI synergies drive moderate upside.\"\n },\n \"bull\": {\n \"target_price\": 16.50,\n \"prob\": 0.20,\n \"notes\": \"Rapid margin recovery, successful deleveraging, and falling Selic rates trigger a multiple re-rating.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (WACC 12.5%, 6.5x exit EV/EBITDA) and historical multiple reversion. The BUY rating reflects a 16% upside to the 13.00 BRL 12M target, balancing turnaround potential against high leverage and MLR risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "EquityResearch-HAPV3", "risks": [ "Persistent inflation in medical costs, drugs, and hospital supplies.", "Regulatory changes by ANS limiting price adjustments or mandating new coverages.", "High interest rates increasing the burden of the 19.3B BRL total debt.", "Increased competition from regional verticalized players and traditional insurers." ], "ticker": "HAPV3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual MLR improvement and steady realization of GNDI synergies drive moderate upside.", "target_price": 13 }, "bear": { "prob": 0.25, "notes": "MLR remains elevated and high interest rates severely pressure cash flow generation.", "target_price": 8.5 }, "bull": { "prob": 0.2, "notes": "Rapid margin recovery, successful deleveraging, and falling Selic rates trigger a multiple re-rating.", "target_price": 16.5 } }, "confidence": 0.65, "assumptions": { "wacc": 0.125, "revenue_cagr_3y": 0.06, "terminal_multiple": 6.5, "ebit_margin_target": 0.08 }, "key_drivers": [ { "driver": "Medical Loss Ratio (MLR)", "impact": "HIGH", "direction": "NEG" }, { "driver": "Ticket Price Adjustments", "impact": "HIGH", "direction": "POS" }, { "driver": "GNDI Integration Synergies", "impact": "MED", "direction": "POS" }, { "driver": "Selic Interest Rate", "impact": "HIGH", "direction": "NEG" }, { "driver": "Beneficiary Base Growth", "impact": "MED", "direction": "POS" }, { "driver": "Hospital Capacity Utilization", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (WACC 12.5%, 6.5x exit EV/EBITDA) and historical multiple reversion. The BUY rating reflects a 16% upside to the 13.00 BRL 12M target, balancing turnaround potential against high leverage and MLR risks. Not investment advice.", "current_price": 11.19, "recommendation": "BUY", "thesis_bullets": [ "Verticalized model offers structural cost advantages over traditional fee-for-service healthcare peers.", "GNDI integration synergies are gradually materializing, supporting long-term margin expansion.", "High medical loss ratio (MLR) remains a near-term headwind but shows signs of stabilization.", "Elevated financial leverage pressures net income amid a high interest rate environment.", "Valuation at ~5.2x EV/EBITDA largely prices in current operational and macroeconomic headwinds." ], "target_price_6m": 12, "target_price_12m": 13 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26155, "createdAt": "2026-04-09T04:18:20.053Z", "usage": { "inputTokens": 2450, "outputTokens": 881, "costUsd": 0.015472 } }, { "id": "cmnqyvh9500itp658j3wu00l5", "runId": "cmnqyvh9300isp658h4zcjfh3", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"HAPV3\",\"currency\":\"BRL\",\"current_price\":11.19,\"target_price_6m\":12.1,\"target_price_12m\":13.2,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Low EV/EBITDA and EV/revenue already discount major execution risk.\",\"Positive FCF supports deleveraging despite slightly negative net earnings.\",\"Verticalized care model can lift margins as utilization normalizes.\",\"High debt and thin profitability cap near-term rerating potential.\",\"Turnaround signs are improving, but evidence remains mixed.\"],\"key_drivers\":[{\"driver\":\"Medical cost trend\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Plan repricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Synergy capture\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cash generation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net leverage\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Interest rates\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory environment\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Membership growth\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Medical inflation spikes again\",\"Premium repricing lags costs\",\"Integration or execution setbacks\",\"Leverage and refinancing pressure\",\"Adverse regulation or litigation\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.06,\"wacc\":0.13,\"terminal_multiple\":6},\"scenarios\":{\"bear\":{\"target_price\":8.5,\"prob\":0.25,\"notes\":\"Margins stall and leverage concerns keep valuation compressed.\"},\"base\":{\"target_price\":13.2,\"prob\":0.5,\"notes\":\"Gradual margin recovery and FCF support moderate rerating.\"},\"bull\":{\"target_price\":17,\"prob\":0.25,\"notes\":\"Faster claims normalization drives stronger earnings and deleveraging.\"}},\"method_notes\":\"Snapshot quote used as authoritative. 12M target based on blended EV/EBITDA and FCF rerating with margin recovery assumptions; no sell-side targets used. Snapshot fundamentals show some internal inconsistencies (e.g., shares/PB), so confidence is moderate. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Model Recommendation", "risks": [ "Medical inflation spikes again", "Premium repricing lags costs", "Integration or execution setbacks", "Leverage and refinancing pressure", "Adverse regulation or litigation" ], "ticker": "HAPV3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual margin recovery and FCF support moderate rerating.", "target_price": 13.2 }, "bear": { "prob": 0.25, "notes": "Margins stall and leverage concerns keep valuation compressed.", "target_price": 8.5 }, "bull": { "prob": 0.25, "notes": "Faster claims normalization drives stronger earnings and deleveraging.", "target_price": 17 } }, "confidence": 0.63, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.08, "terminal_multiple": 6, "ebit_margin_target": 0.06 }, "key_drivers": [ { "driver": "Medical cost trend", "impact": "HIGH", "direction": "POS" }, { "driver": "Plan repricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Synergy capture", "impact": "HIGH", "direction": "POS" }, { "driver": "Cash generation", "impact": "MED", "direction": "POS" }, { "driver": "Net leverage", "impact": "HIGH", "direction": "NEG" }, { "driver": "Interest rates", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" }, { "driver": "Membership growth", "impact": "MED", "direction": "POS" } ], "method_notes": "Snapshot quote used as authoritative. 12M target based on blended EV/EBITDA and FCF rerating with margin recovery assumptions; no sell-side targets used. Snapshot fundamentals show some internal inconsistencies (e.g., shares/PB), so confidence is moderate. not investment advice", "current_price": 11.19, "recommendation": "BUY", "thesis_bullets": [ "Low EV/EBITDA and EV/revenue already discount major execution risk.", "Positive FCF supports deleveraging despite slightly negative net earnings.", "Verticalized care model can lift margins as utilization normalizes.", "High debt and thin profitability cap near-term rerating potential.", "Turnaround signs are improving, but evidence remains mixed." ], "target_price_6m": 12.1, "target_price_12m": 13.2 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_06f153e9148208fa0069d72a638e0081968b7e9d21fc0000df", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24268, "createdAt": "2026-04-09T04:18:20.053Z", "usage": { "inputTokens": 2463, "outputTokens": 1464, "costUsd": 0.024806 } }, { "id": "cmnqyvh9500iwp658ofn56hxm", "runId": "cmnqyvh9300isp658h4zcjfh3", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF Scenario Valuation Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"HAPV3\",\n \"currency\": \"BRL\",\n \"current_price\": 11.19,\n \"target_price_6m\": 12.8,\n \"target_price_12m\": 14.5,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Vertical integration aids cost control and margin recovery\",\n \"Scale leadership supports beneficiary growth over time\",\n \"High debt burden raises vulnerability to rate volatility\",\n \"Regulatory pressures from ANS limit pricing power\",\n \"Improving sinistrality trends drive operational leverage\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical loss ratio trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory interventions\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Revenue per beneficiary growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Net debt reduction pace\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Integration execution\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive pressure\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Persistent negative earnings and cash burn\",\n \"ANS regulatory tightening on premiums\",\n \"Rising medical inflation above expectations\",\n \"Debt servicing strain in high-rate scenario\",\n \"Integration delays with NotreDame\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.09,\n \"ebit_margin_target\": 0.08,\n \"wacc\": 0.115,\n \"terminal_multiple\": 9\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 9.2,\n \"prob\": 0.35,\n \"notes\": \"Margins stay compressed on regulatory and cost pressures.\"\n },\n \"base\": {\n \"target_price\": 14.5,\n \"prob\": 0.45,\n \"notes\": \"Gradual margin recovery to 8% with stable growth.\"\n },\n \"bull\": {\n \"target_price\": 18.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated efficiencies and beneficiary gains beat forecasts.\"\n }\n },\n \"method_notes\": \"3-stage DCF with revenue CAGR, target EBIT margin, WACC 11.5% and 9x terminal EV/EBIT. Base case implies ~30% upside. Consensus targets not used as input. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "DCF Scenario Valuation Model", "risks": [ "Persistent negative earnings and cash burn", "ANS regulatory tightening on premiums", "Rising medical inflation above expectations", "Debt servicing strain in high-rate scenario", "Integration delays with NotreDame" ], "ticker": "HAPV3", "currency": "BRL", "scenarios": { "base": { "prob": 0.45, "notes": "Gradual margin recovery to 8% with stable growth.", "target_price": 14.5 }, "bear": { "prob": 0.35, "notes": "Margins stay compressed on regulatory and cost pressures.", "target_price": 9.2 }, "bull": { "prob": 0.2, "notes": "Accelerated efficiencies and beneficiary gains beat forecasts.", "target_price": 18 } }, "confidence": 0.62, "assumptions": { "wacc": 0.115, "revenue_cagr_3y": 0.09, "terminal_multiple": 9, "ebit_margin_target": 0.08 }, "key_drivers": [ { "driver": "EBIT margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical loss ratio trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory interventions", "impact": "HIGH", "direction": "NEG" }, { "driver": "Revenue per beneficiary growth", "impact": "MED", "direction": "POS" }, { "driver": "Net debt reduction pace", "impact": "MED", "direction": "POS" }, { "driver": "Interest rate environment", "impact": "MED", "direction": "NEG" }, { "driver": "Integration execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "3-stage DCF with revenue CAGR, target EBIT margin, WACC 11.5% and 9x terminal EV/EBIT. Base case implies ~30% upside. Consensus targets not used as input. Not investment advice.", "current_price": 11.19, "recommendation": "BUY", "thesis_bullets": [ "Vertical integration aids cost control and margin recovery", "Scale leadership supports beneficiary growth over time", "High debt burden raises vulnerability to rate volatility", "Regulatory pressures from ANS limit pricing power", "Improving sinistrality trends drive operational leverage" ], "target_price_6m": 12.8, "target_price_12m": 14.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "db89e9f2-ab39-9961-a0e8-63083721e7c4", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 19171, "createdAt": "2026-04-09T04:18:20.053Z", "usage": { "inputTokens": 2803, "outputTokens": 2867, "costUsd": 0.051414 } } ] } }